Intercell's Adjuvant Patch Fails to Boost Pandemic Flu Vaccine July 7, 2010 By Cormac Sheridan A faulty hemagglutinin inhibition assay may be the reason underlying the failure of a Phase II clinical trial of Intercell AG's investigational Vaccine Enhancement Patch (VEP) for H5N1 influenza. (BioWorld International)Read More
RSS